Bayer's Science and Its Sales Are Two Different Bets, and November Will Test Only One
Published on 10/20/2026 at 07:20 | Editorial boerse-global.de
Bayer investors face a question that sounds simpler than it is: should a drug pipeline's forward motion be allowed to stand in for earnings that have not yet arrived? The company's recent flow of announcements — a trial under way, a regulatory filing accepted — offers genuine reasons for long-term interest. None of them, however, puts a single euro of additional revenue on the books.
That distinction sharpens with each passing week, because a hard date now anchors the calendar. Bayer has scheduled its third-quarter 2026 interim report for 3 November, alongside a media update and an investor call. Until those figures land, the operating side of the investment case rests largely on expectation rather than evidence.
What the laboratory has actually delivered
Over at Vividion Therapeutics, the group's subsidiary, the first patient has been dosed in a global Phase II combination study pairing VVD-214 with pembrolizumab. The trial targets previously untreated patients with advanced MSI-high or dMMR colorectal cancer — a deliberately narrow population, not colorectal disease at large. "Previously untreated" refers to the first-line setting in advanced illness, not to early-stage disease.
The dosing of that initial patient marks a step completed inside a study programme. It says nothing yet about whether the combination works. Anyone reading a therapeutic benefit, let alone a commercial one, into a trial's opening is running well ahead of the evidence.
A second thread runs through the regulatory side. Roughly two weeks ago, the US Food and Drug Administration accepted Bayer's supplemental application for Kerendia (finerenone) in chronic kidney disease associated with type 2 diabetes — the filing rests on data from the Phase III FIND-CKD trial. Acceptance is a procedural milestone. It is not an approval, and it does not arrive automatically as one.
Should investors sell immediately? Or is it worth buying Bayer?
Why the two announcements resist a single label
The temptation to bundle these developments into one story of a "growth push" misreads both. One is an accepted marketing application; the other is a clinical programme that has just begun enrolling and treating. Their evidentiary weight differs, and neither converts directly into sales or profit.
That gap matters most when sentiment is running ahead of the numbers. An investor leaning on the research narrative is weighting future probabilities above present results; one waiting for the quarterly figures gets an extra checkpoint on how the existing business is actually performing. Neither approach removes the uncertainty — what separates them is the kind of confirmation each thesis demands, and how much disappointment each can absorb.
The analyst voice on one side of the ledger
UBS supplied a counterweight to caution on 14 October, restating a "Buy" rating with a price target of EUR 62. Analyst Matthew Weston pointed to anticipated results as well as developments in the agricultural and pharmaceutical businesses. That view is an assessment, not a guaranteed outcome, and it does not substitute for examining the actual numbers. The real test is whether trading matches an investor's own expectations — not merely whether an analyst still sees upside.
The scenario that would hurt most
A constructive case for Bayer would combine an operating performance that bolsters confidence with room to value the longer-dated research options. The pessimistic version is not necessarily a trial setback. It is an operating performance that falls short of what shareholders have come to expect — leaving the pipeline intact but far less persuasive for near-term valuation. Even a supportive analyst rating does nothing to neutralise that risk. The more an investor's thesis leans on future successes, the more vital the line between a possible long-term opportunity and an improvement already demonstrated becomes.
November as a reclassification exercise
Should clinical work keep advancing while the underlying business carries expectations, a positive view of Bayer could harden. If the read on current trading flips, procedural progress alone will struggle to offset it. These are alternative scenarios, not pre-announced results.
The value of the 3 November update lies in the chance to re-sort the operating picture. The sturdier investment case will be the one that holds business results and research prospects together without blurring how differently each proves its point.
Ad
Bayer Stock: New Analysis - 20 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
